Colon-targeted delivery of cyclosporine A using dual-functional Eudragit^® FS30D/PLGA nanoparticles ameliorates murine experimental colitis

References

• TravisSPDaneseSKupcinskasLOnce-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II studyGut201463343344123436336
   PubMed Web of Science ®Google Scholar
• FrankDNAmandALStFeldmanRABoedekerECHarpazNPaceNRMolecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseasesProc Natl Acad Sci U S A200710434137801378517699621
   PubMed Web of Science ®Google Scholar
• RoglerGChronic ulcerative colitis and colorectal cancerCancer Lett2014345223524123941831
   PubMed Web of Science ®Google Scholar
• BurgerDTravisSConventional medical management of inflammatory bowel diseaseGastroenterology2011140618271837.e221530749
   PubMed Web of Science ®Google Scholar
• ParkSCJeenYTCurrent and emerging biologics for ulcerative colitisGut Liver201591182725547087
   PubMed Web of Science ®Google Scholar
• ActisGCFaddaMDavidESapinoAColectomy rate in steroid-refractory colitis initially responsive to cyclosporin: a long-term retrospective cohort studyBMC Gastroenterol2007711317389040
   PubMedGoogle Scholar
• CohenRDSteinRHanauerSBIntravenous cyclosporin in ulcerative colitis: a five-year experienceAm J Gastroenterol19999461587159210364029
   PubMed Web of Science ®Google Scholar
• BeauchesnePRChungNSWasanKMCyclosporine A: a review of current oral and intravenous delivery systemsDrug Dev Ind Pharm200733321122017454054
   PubMed Web of Science ®Google Scholar
• EunCSHanDSDoes the cyclosporine still have a potential role in the treatment of acute severe steroid-refractory ulcerative colitis?Gut Liver20159556756826343066
   PubMed Web of Science ®Google Scholar
• AberraFNLichtensteinGRReview article: monitoring of immunomodulators in inflammatory bowel diseaseAliment Pharmacol Ther200521430731915709982
   PubMed Web of Science ®Google Scholar
• DaiJNagaiTWangXZhangTMengMZhangQpH-sensitive nanoparticles for improving the oral bioavailability of cyclosporine AInt J Pharm2004280122924015265562
   PubMedGoogle Scholar
• MaheshVNCampbellRAhluwaliaNKW1330 cyclosporine enema in conventional ± immunomodulator refractory distal ulcerative colitis: ready for prime time or hype?Gastroenterology20101385S-700
   Web of Science ®Google Scholar
• SandbornWJStrongRMForlandSCChaseRECutlerREThe pharmacokinetics and colonic tissue concentrations of cyclosporine after i.v., oral, and enema administrationJ Clin Pharmacol199131176802045532
   PubMed Web of Science ®Google Scholar
• YoushiaJLamprechtASize-dependent nanoparticulate drug delivery in inflammatory bowel diseasesExpert Opin Drug Deliv201613228129426637060
   PubMed Web of Science ®Google Scholar
• NaeemMCaoJChoiMEnhanced therapeutic efficacy of budesonide in experimental colitis with enzyme/pH dual-sensitive polymeric nanoparticlesInt J Nanomedicine2015104565458026213469
   PubMed Web of Science ®Google Scholar
• VongLBMoJAbrahamssonBNagasakiYSpecific accumulation of orally administered redox nanotherapeutics in the inflamed colon reducing inflammation with dose–response efficacyJ Control Release2015210192525998050
   PubMed Web of Science ®Google Scholar
• HuaSMarksESchneiderJJKeelySAdvances in oral nano-delivery systems for colon targeted drug delivery in inflammatory bowel disease: selective targeting to diseased versus healthy tissueNanomedicine20151151117113225784453
   PubMed Web of Science ®Google Scholar
• GuadaMBeloquiAAlhouayekMCyclosporine A-loaded lipid nanoparticles in inflammatory bowel diseaseInt J Pharm2016503119619826972380
   PubMed Web of Science ®Google Scholar
• CourthionHMugnierTRousseauxCMöllerMGurnyRGabrielDSelf-assembling polymeric nanocarriers to target inflammatory lesions in ulcerative colitisJ Control Release2017275323928774843
   PubMed Web of Science ®Google Scholar
• MeleroADraheimCHansenSTargeted delivery of Cyclosporine A by polymeric nanocarriers improves the therapy of inflammatory bowel disease in a relevant mouse modelEur J Pharm Biopharm201711936137128709903
   PubMed Web of Science ®Google Scholar
• AliHWeigmannBNeurathMCollnotEWindbergsMLehrC-MBudesonide loaded nanoparticles with pH-sensitive coating for improved mucosal targeting in mouse models of inflammatory bowel diseasesJ Control Release201418316717724685705
   PubMed Web of Science ®Google Scholar
• NaeemMChoiMCaoJColon-targeted delivery of budesonide using dual pH-and time-dependent polymeric nanoparticles for colitis therapyDrug Des Devel Ther2015937893799
   PubMed Web of Science ®Google Scholar
• AksungurPDemirbilekMDenkbaşEBVandervoortJLudwigAÜnlüNDevelopment and characterization of Cyclosporine A loaded nanoparticles for ocular drug delivery: cellular toxicity, uptake, and kinetic studiesJ Control Release2011151328629421241752
   PubMed Web of Science ®Google Scholar
• SunSLiangNYamamotoHKawashimaYCuiFYanPpH-sensitive poly(lactide-co-glycolide) nanoparticle composite microcapsules for oral delivery of insulinInt J Nanomedicine2015103489349825999713
   PubMed Web of Science ®Google Scholar
• BeloquiACocoRMemvangaPBUcakarBdes RieuxAPréatVpH-sensitive nanoparticles for colonic delivery of curcumin in inflammatory bowel diseaseInt J Pharm20144731–220321225014369
   PubMed Web of Science ®Google Scholar
• VandammeTFLenourryACharrueauCChaumeilJ-CThe use of polysaccharides to target drugs to the colonCarbohydr Polym2002483219231
   Web of Science ®Google Scholar
• HartmannGBidlingmaierCSiegmundBSpecific type IV phosphodiesterase inhibitor rolipram mitigates experimental colitis in miceJ Pharmacol Exp Ther20002921223010604928
   PubMed Web of Science ®Google Scholar
• MakhlofATozukaYTakeuchiHpH-Sensitive nanospheres for colon-specific drug delivery in experimentally induced colitis rat modelEur J Pharm Biopharm20097211819348015
   PubMed Web of Science ®Google Scholar
• ViennoisEXiaoBAyyaduraiSMicheliolide, a new sesquiterpene lactone that inhibits intestinal inflammation and colitis-associated cancerLab Invest201494995096525068660
   PubMed Web of Science ®Google Scholar
• WeigmannBLehrHAYancopoulosGThe transcription factor NFATc2 controls IL-6-dependent T cell activation in experimental colitisJ Exp Med200820592099211018710929
   PubMed Web of Science ®Google Scholar
• KimJJShajibMSManochaMMKhanWIInvestigating intestinal inflammation in DSS-induced model of IBDJ Vis Exp201260e3678
   PubMed Web of Science ®Google Scholar
• LamprechtASchäferULehrC-MSize-dependent bioadhesion of micro- and nanoparticulate carriers to the inflamed colonic mucosaPharm Res200118678879311474782
   PubMed Web of Science ®Google Scholar
• WatanabeATanakaHSakuraiYEffect of particle size on their accumulation in an inflammatory lesion in a dextran sulfate sodium (DSS)-induced colitis modelInt J Pharm20165091–211812227231121
   PubMedGoogle Scholar
• ReineckerHCSteffenMWitthoeftTEnhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn’s diseaseClin Exp Immunol19939411741818403503
   PubMed Web of Science ®Google Scholar
• ArtsJD’HaensGZeegersMLong-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitisInflamm Bowel Dis2004102737815168804
   PubMed Web of Science ®Google Scholar
• JärnerotGRolnyPSandberg-GertzénHIntensive intravenous treatment of ulcerative colitisGastroenterology1985895100510133930339
   PubMed Web of Science ®Google Scholar
• LichtigerSPresentDHKornbluthACyclosporine in severe ulcerative colitis refractory to steroid therapyN Engl J Med199433026184118458196726
   PubMed Web of Science ®Google Scholar
• D’HaensGLemmensLNevensFIntravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitisGastroenterology200112061323132911313301
   PubMed Web of Science ®Google Scholar
• LamprechtAIBD: selective nanoparticle adhesion can enhance colitis therapyNat Rev Gastroenterol Hepatol20107631131220523352
   PubMed Web of Science ®Google Scholar
• NugentSKumarDRamptonDSEvansDFIntestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugsGut200148457157711247905
   PubMed Web of Science ®Google Scholar
• ViscidoACapannoloALatellaGCaprilliRFrieriGNanotechnology in the treatment of inflammatory bowel diseasesJ Crohns Colitis20148990391824686095
   PubMed Web of Science ®Google Scholar
• LamprechtAYamamotoHTakeuchiHKawashimaYNanoparticles enhance therapeutic efficiency by selectively increased local drug dose in experimental colitis in ratsJ Pharmacol Exp Ther2005315119620215980057
   PubMed Web of Science ®Google Scholar
• MaXWilliamsROPolymeric nanomedicines for poorly soluble drugs in oral delivery systems: an updateJ Pharm Invest20184816175
   Google Scholar
• PawarPKGautamCDesign, optimization and evaluation of mesalamine matrix tablet for colon drug delivery systemJ Pharm Invest20164616778
   Google Scholar
• GuadaMLanaHGilAGdel Carmen Dios-ViéitezMBlanco-PrietoMJCyclosporine A lipid nanoparticles for oral administration: pharmacodynamics and safety evaluationEur J Pharm Biopharm201610111211826877154
   PubMed Web of Science ®Google Scholar
• SannHvon ErichsenJHessmannMPahlAHoffmeyerAEfficacy of drugs used in the treatment of IBD and combinations thereof in acute DSS-induced colitis in miceLife Sci2013921270871823399699
   PubMed Web of Science ®Google Scholar
• WirtzSNeurathMFMouse models of inflammatory bowel diseaseAdv Drug Deliv Rev200759111073108317825455
   PubMed Web of Science ®Google Scholar
• MendozaJAbreuMBiological markers in inflammatory bowel disease: practical consideration for cliniciansGastroenterol Clin Biol200933S158S17320117339
   PubMedGoogle Scholar